Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07336056 · ClinicalTrials.gov registry record · Phase 4
Nerivio Efficacy Under High-Frequency Use
A Phase 4 study of Migraine, sponsored by Theranica.
- Active
- Registry status
- Phase 4
- Development phase
- 2,000
- Enrollment target
- 1
- Study location
NCT07336056 is a Phase 4 study of Migraine that is active but no longer recruiting, run by Theranica. The registered enrollment target is 2,000 participants, above the 339-participant average among 102 other Migraine trials with a reported enrollment target (490% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07336056, a Phase 4 study of Migraine, is active but no longer recruiting, sponsored by Theranica.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Post-marketing study investigating the impact of frequant usage with Nerivio on the safety profile of Remote Electrical Neuromodulation (REN) for the treatment of migraine. This study assessed the safety and tolerability of REN when used at frequencies exceeding the labeled indication.
Conditions Studied
Interventions
- DEVICE Nerivio (REN device)
Study Locations (1)
New Jersey
- Theranica USA Inc - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07336056
The ClinicalTrials.gov registry entry for NCT07336056 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 339-participant average among 102 other Migraine trials with a reported enrollment target (490% higher). The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Nerivio (REN device) is the first listed.
NCT07336056 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT07336056 about?
NCT07336056 is a clinical study titled "Nerivio Efficacy Under High-Frequency Use". This is a Post-marketing study investigating the impact of frequant usage with Nerivio on the safety profile of Remote Electrical Neuromodulation (REN) for the treatment of migraine. This study assessed the safety and tolerability of REN when used at frequencies exceeding the labeled indication.
What is the current status of trial NCT07336056?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 2,000 participants. The study started on 2026-01-08. Estimated completion is 2026-01-30.
What conditions does trial NCT07336056 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT07336056?
The interventions under investigation include: Nerivio (REN device) (DEVICE).
Who is sponsoring clinical trial NCT07336056?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07336056 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
-
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.